ImmuCell Corporation

Total Valuation

ImmuCell Corporation carries a market capitalization of 101.28M, placing it among publicly traded companies globally. Its enterprise value stands at 63.20M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

ImmuCell Corporation currently has 9.05M shares outstanding.

Valuation Ratios

ImmuCell Corporation trades at a trailing price-to-earnings ratio of 89.57. The price-to-sales ratio is 1.91, and the price-to-book ratio stands at -4.63.

Enterprise Valuation

On an enterprise value basis, ImmuCell Corporation trades at an EV/EBITDA multiple of 12.43 and an EV/FCF ratio of 10.50. The EV/Sales ratio of 2.11 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 25.27 provides insight into valuation relative to core operating earnings.

Financial Position

ImmuCell Corporation maintains a current ratio of 4.82, meaning it holds 4.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 43.86, indicating elevated leverage, while an interest coverage ratio of 11.84 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, ImmuCell Corporation has paid 22,188.00 in income taxes, reflecting an effective tax rate of 1.02.

Stock Price Statistics

ImmuCell Corporation's stock has gained approximately 63.90922% over the past 52 weeks. The 50-day moving average sits at 9.98, while the 200-day moving average is 7.31.

Income Statement

Over the trailing twelve months, ImmuCell Corporation generated 29.93M in revenue and converted that into -545,403.00 in net income, yielding earnings per share of -0.06. EBITDA reached 5.08M, while operating income came in at 2.50M.

Balance Sheet

ImmuCell Corporation holds 6.81M in cash and equivalents against 12.78M in total debt, resulting in a net debt position of 1.89M. Total book value stands at -12.35M, with working capital of 14.95M providing operational flexibility.

Cash Flow

ImmuCell Corporation produced 4.47M in operating cash flow over the past twelve months. After subtracting -1.10M in capital expenditures, free cash flow totaled 3.38M - equivalent to 0.37 per share.

Margins

ImmuCell Corporation operates with a gross margin of 42.59, reflecting its pricing power and cost economics. The operating margin of 8.35 and net profit margin of -1.82 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

ImmuCell Corporation's most recent stock split took place on July 25, 1990 with a 100:1 split ratio.

Scores

ImmuCell Corporation posts an Altman Z-Score of 3.15, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.